Search results (41)
Page
Article
With the right formulary, plans can control drug costs while preserving access
Each plan determines which formulary is best for its unique circumstances.
Read More
Article
Study: Progression of cardiodiabesity increases care utilization and costs
The Evernorth Research Institute’s latest cardiodiabesity report helps illustrate sites of care where preventive interventions can make the greatest financial impact.
Read More
expert
Page
Page
Page
Article
Easing the impact of GLP-1s
With GLP-1 sales forecast to exceed $100 billion, plan sponsors need the tools to control growth and expand access.
Read More
Press Release
Evernorth Announces Industry-First Financial Guarantee For GLP-1 Spend
EncircleRx solution now includes financial predictability for health plan sponsors to help expand access for appropriate patients.
Read More
Article
Clinically Speaking: Boosting Biosimilars Competition and Savings
An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...
Read More